BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 28, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

TMC435: Phase III started

Medivir said Johnson & Johnson's Tibotec Pharmaceuticals Ltd. unit began the double-blind, placebo-controlled, international Phase III QUEST-1 trial in 375 treatment-naïve patients with HCV genotype 1 to evaluate 150...

Read the full 125 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >